

# Anargyros Xenocostas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10040608/publications.pdf>

Version: 2024-02-01

33  
papers

317  
citations

1040056

9  
h-index

839539

18  
g-index

33  
all docs

33  
docs citations

33  
times ranked

638  
citing authors

#	ARTICLE	IF	CITATIONS
1	The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 189-195.	1.9	97
2	A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 1935-1945.	5.2	34
3	Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1463-1473.	1.6	32
4	Transfusion of Red Cells in Hematopoietic Stem Cell Transplantation (TRIST Study): A Randomized Controlled Trial Evaluating 2 Red Cell Transfusion Thresholds. <i>Blood</i> , 2016, 128, 1032-1032.	1.4	22
5	Implementation of an NGS-based sequencing and gene fusion panel for clinical screening of patients with suspected hematologic malignancies. <i>European Journal of Haematology</i> , 2019, 103, 178-189.	2.2	21
6	Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial. <i>Blood</i> , 2018, 132, 787-787.	1.4	17
7	Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1813-1818.	2.0	16
8	Quality of life trajectories during the first year following hematopoietic cell transplantation: an inception cohort study. <i>Supportive Care in Cancer</i> , 2018, 26, 2379-2386.	2.2	11
9	Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial. <i>Blood</i> , 2016, 128, 1922-1922.	1.4	11
10	Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial. <i>British Journal of Haematology</i> , 2021, 193, 779-791.	2.5	10
11	Transfusion of Red Blood Cells under Shock Conditions in the Rat Microvasculature.. <i>Blood</i> , 2004, 104, 2713-2713.	1.4	9
12	Clinical value of next-generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2021, 192, 729-736.	2.5	8
13	Improved Prediction of CD34 + Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 763-767.	2.0	6
14	Abnormal dopamine receptor signaling allows selective therapeutic targeting of neoplastic progenitors in AML patients. <i>Cell Reports Medicine</i> , 2021, 2, 100202.	6.5	5
15	Impact of Transition to Generic Imatinib in the Molecular Response Among Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2014, 124, 5527-5527.	1.4	5
16	<i>bcr-abl1</i> transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase. <i>British Journal of Haematology</i> , 2022, 196, 136-145.	2.5	4
17	Safe Start of Ibrutinib in Patients with Chronic Lymphocytic Leukemia and Uncontrolled Autoimmune Hemolytic Anemia. <i>Blood</i> , 2018, 132, 5560-5560.	1.4	4
18	Reducing cytogenetic testing in the era of next generation sequencing: Are we choosing wisely?. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 333-341.	1.3	3

#	ARTICLE	IF	CITATIONS
19	BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure. <i>Blood</i> , 2020, 136, 40-41.	1.4	1
20	The tale of two organs: allogeneic hematopoietic stem cell transplantation following liver transplantation in a myelofibrosis patient. <i>Hematology, Transfusion and Cell Therapy</i> , 2023, 45, 502-504.	0.2	1
21	Response to "Need to Minimize Bias When Surveying Patient Attitudes to Stopping cml Treatment": <i>Current Oncology</i> , 2014, 21, 803-804.	2.2	0
22	A Comparison of Administration Time between Red Blood Cell Transfusion and Chemotherapy.. <i>Blood</i> , 2005, 106, 4186-4186.	1.4	0
23	Red Blood Cell Transfusion and Chemotherapy Administration: A Study of Resource Utilization at the London Regional Cancer Program (LRCP).. <i>Blood</i> , 2006, 108, 4143-4143.	1.4	0
24	Screening for Leptomeningeal Disease by High-Sensitivity Flow Cytometry in High Risk Patients with Aggressive Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2007, 110, 4397-4397.	1.4	0
25	Role of interleukin-33 in sepsis-induced myocardial dysfunction. <i>FASEB Journal</i> , 2012, 26, 835.6.	0.5	0
26	Erythropoietin in Elderly Patients with Anemia of Unknown Etiology. <i>Blood</i> , 2015, 126, 3346-3346.	1.4	0
27	Erythropoiesis-Stimulating Agents in Elderly Patients with Anemia of Unknown Etiology: Treatment Response and Cardiovascular Outcomes. <i>Blood</i> , 2016, 128, 1267-1267.	1.4	0
28	Increasing capacity for autologous stem cell transplants for lymphomas: a quality improvement study. , 2021, , .		0
29	Update of Multicenter, Retrospective Evaluation of Overall Response and Failure Free Survival Following Ruxolitinib Therapy for Heavily Pre-Treated Chronic Gvhd Patients with Steroid-Failure: A Proposal of Risk Score Model for Failure-Free Survival. <i>Blood</i> , 2021, 138, 3905-3905.	1.4	0
30	Risk of Major Bleeding with Ibrutinib in Patients with Thrombocytopenia - a Retrospective Single-Center Canadian Study. <i>Blood</i> , 2021, 138, 4682-4682.	1.4	0
31	Identifying Myeloid Mutations By NGS in Patients with Unexplained Erythrocytosis. <i>Blood</i> , 2020, 136, 47-47.	1.4	0
32	Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial. <i>Blood</i> , 2020, 136, 54-55.	1.4	0
33	Reducing Cytogenetic Testing in the Era of Next Generation Sequencing (NGS); Are We Choosing Wisely?. <i>Blood</i> , 2020, 136, 12-13.	1.4	0